AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - Table II. Carbapenemase-producing carbapenem-resistant Enterobacteriaceae

NNDSS - Table II. Carbapenemase-producing carbapenem-resistant Enterobacteriaceae - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states or territory.

Note:

This table contains provisional cases of selected national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up.  Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html 

Footnotes:

C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable. —: No reported cases. N: Not reportable. NA:  Not Available.  NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Case counts for reporting years 2017 and 2018 are provisional and subject to change. Data for years 2013 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.  

† Data for carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) will be displayed in this table after the CDC obtains Office of Management and Budget Paperwork Reduction Act approval to receive data for this condition.
MD COVID-19 Total Vaccinations by Age - First, Second, Single, and Third Dose

Regarding all Vaccination Data
The date of Last Update is 4/21/2023. Additionally on 4/27/2023 several COVID-19 datasets were retired and no longer included in public COVID-19 data dissemination.

See this link for more information
https://imap.maryland.gov/pages/covid-data

<b>Summary</b>
The cumulative number of COVID-19 vaccinations among Maryland residents by age groupings: 0-9; 10-19; 20-29; 30-39; 40-49; 50-59; 60-69; 70-79; 80+; unknown

<b>Description</b>
MD COVID-19 - Vaccinations by Age Distribution data layer is a collection of COVID-19 vaccinations that have been reported each day into ImmuNet.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Patent AT-E400305-T1: [Translated] FILM-FORMING COMPOSITIONS FOR PROTECTING THE SKIN FROM BODY FLUIDS AND ARTICLES MADE THEREFROM

A film-forming barrier composition useful for protecting the skin from body fluids, such as urine, feces, menses. The composition includes a skin conditioning agent, a viscosity enhancing agent and an oleophilic film-forming agent. Optionally, the lotion may include a skin care ingredients for treating or maintaining skin health. The composition may be applied to the skin by suitable delivery vehicles, such as absorbent articles or components thereof, sheet materials, pads, bandages, sponges, foam pads, pumps, sprays, depending on the viscosity of the composition.
Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity

Background
          The p53 protein is activated by genotoxic stress, oncogene expression and during senescence, p53 transcriptionally activates genes involved in growth arrest and apoptosis. p53 activation is regulated by post-translational modification, including phosphorylation of the N-terminal transactivation domain. Here, we have examined how Glycogen Synthase Kinase (GSK3), a protein kinase involved in tumorigenesis, differentiation and apoptosis, phosphorylates and regulates p53.
        
        
          Results
          The 2 isoforms of GSK3, GSK3α and GSK3β, phosphorylate the sequence Ser-X-X-X-Ser(P) when the C-terminal serine residue is already phosphorylated. Several p53 kinases were examined for their ability to create GSK3 phosphorylation sites on the p53 protein. Our results demonstrate that phosphorylation of serine 37 of p53 by DNA-PK creates a site for GSK3β phosphorylation at serine 33 in vitro. GSK3α did not phosphorylate p53 under any condition. GSK3β increased the transcriptional activity of the p53 protein in vivo. Mutation of either serine 33 or serine 37 of p53 to alanine blocked the ability of GSK3β to regulate p53 transcriptional activity. GSK3β is therefore able to regulate p53 function in vivo. p53's transcriptional activity is commonly increased by DNA damage. However, GSK3β kinase activity was inhibited in response to DNA damage, suggesting that GSK3β regulation of p53 is not involved in the p53-DNA damage response.
        
        
          Conclusions
          GSK3β can regulate p53's transcriptional activity by phosphorylating serine 33. However, GSK3β does not appear to be part of the p53-DNA damage response pathway. Instead, GSK3β may provide the link between p53 and non-DNA damage mechanisms for p53 activation.
Phylogenetic relationships between

Background
          Phylogenetic relationships of the genus Hapalemur remains controversial, particularly within the Hapalemur griseus species group. In order to obtain more information on the taxonomic status within this genus, and particularly in the cytogenetic distinct subspecies group of Hapalemur griseus, 357 bp sequence of cytochrome b and 438 bp of 12S mitochondrial DNAs were analyzed on a sample of animals captured in areas extending from the north to the south-east of Madagascar. This sample covers all cytogenetically defined types recognized of the genus Hapalemur.
        
        
          Results
          Phylogenetic trees and distances analyses demonstrate a first emergence of Hapalemur simus followed by H. aureus which is the sister clade of the H. griseus subspecies. Hapalemur griseus is composed of 4 subspecies separated into two clades. The first contains H. g. griseus, H. g. alaotrensis and H. g. occidentalis. The second consists of H. g. meridionalis. A new chromosomal polymorphic variant from the region of Ranomafana, H. griseus ssp, has been analysed and was found in both clades.
        
        
          Conclusions
          Our results support the raising of H. g. meridionalis to the specific rank H. meridionalis, while neither cytogenetic nor molecular evidences support the raising of H. g. alaotrensis to a species rank despite its morphological characteristics. The new cytotype H. g. ssp which has been previously characterized by cytogenetic studies contains animals clustering either with the group of Hapalemur griseus griseus or with that of Hapalemur meridionalis. This suggests the existence of an ancestral polymorphism or an introgression of mitochondrial DNA between subspecies.
Drug Abuse Warning Network (DAWN-2005)

<p>The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.<br />
DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.<br />
The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year.  Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.</p>
Compound 525149: Dipropylene glycol, monoallyl ether, acetate

Chemical compound data from PubChem database. IUPAC Name: 2-(2-prop-2-enoxypropoxy)propyl acetate. Molecular Formula: C11H20O4. Molecular Weight: 216.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530057: 5beta-Pregnane-3alpha,17,20alpha-triol, cyclic 17,20-methaneboronate

Chemical compound data from PubChem database. IUPAC Name: 2',5',10,13-tetramethylspiro[1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-17,4'-1,3,2-dioxaborolane]-3-ol. Molecular Formula: C22H37BO3. Molecular Weight: 360.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400085-T1: [Translated] MONOLITHIC FBAR DUPLEXER AND METHOD FOR PRODUCING SAME

A monolithic bulk acoustic wave (BAW) duplexer, and a method for fabricating same, the duplexer having a transmitter section as a first component filter and a receiver section as a second component filter, both component filters fabricated on a single substrate and both including at least one shunt BAW resonator and one series BAW resonator, each BAW resonator including a resonator section atop an isolation structure provided so as to separate the resonator section from the substrate, including: a patterned bottom electrode material for use as the bottom electrode of each of the resonators of the duplexer; a patterned piezoelectric material for use as the piezolayer of each of the resonators of the duplexer; a patterned top electrode material for use as the top electrode of each of the resonators of the duplexer; a tuning layer for the shunt resonator of each of the two component duplexer filters; and a tuning layer for both the series and shunt resonators of one of the two component duplexer filters. In some applications, each isolation structure is an acoustic mirror. Also in some applications, the duplexer further includes at least one planar spiral inductor provided in the course of depositing one or another layer of material in building up the duplexer, the planar spiral inductor having coils spiraling outward substantially in a plane from an innermost coil to an outermost coil. <IMAGE>
New York City – 5 Boros: Drug-Related Emergency Department Visits, 2004-2011 - Accidental Ingestions

Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving accidental ingestions in New York City (5 boroughs). This analytic category includes ED visits in which an individual accidentally or unknowingly used or was administered a prescription drug, over-the-counter medication, or dietary supplement. Drug-related accidental ingestion typically involves patients aged 5 and under.  This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Compound 525245: N''-(4-bromo-phenyl)-N,N,N',N'-tetramethyl-guanidine

Chemical compound data from PubChem database. IUPAC Name: 2-(4-bromophenyl)-1,1,3,3-tetramethylguanidine. Molecular Formula: C11H16BrN3. Molecular Weight: 270.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Second National Juvenile Online Victimization Study (NJOV-2)

The Second National Juvenile Online Victimization Study (NJOV-2) was conducted in 2007-2008 and designed to update and expand upon the First National Juvenile Online Victimization Study (NJOV-1) conducted in 2001-2002. Researchers collected information from a national sample of more than 2,500 law enforcement agencies about Internet sex crimes against minors during 2006, providing detailed information about the types of Internet sex crimes, as well as numbers of arrests, characteristics of offenders and victims, dynamics of the crimes, and criminal justice system responses. Data, which are weighted to provide national estimates, were collected via mail surveys followed by telephone interviews with investigators about specific cases reported in the mail surveys.

Investigators: Finkelhor, D., Mitchell, K., & Wolak, J.
The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice

The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study was the first trial to assess whether statins might be of clinical benefit in those with recently unstable coronary disease. MIRACL found that high-dose atorvastatin was safe and reduced the incidence of the composite endpoint, death, non-fatal myocardial infarction, resuscitated sudden cardiac death or emergent rehospitalization for recurrent ischemia at 16 weeks when compared with placebo. Despite a number of important study limitations, MIRACL's findings and the prior observation that inpatient initiation of lipid-lowering therapy is associated with higher rates of subsequent utilization, suggest that it is prudent to begin statin therapy when patients present with an acute coronary syndrome.
National Directory of Drug and Alcohol Abuse Treatment Facilities 2001

The National Directory of Drug and Alcohol Abuse Treatment Programs 2001 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 2000 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 2000 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
2012 Uniform Reporting System (URS) Tables for Delaware

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Mississippi (MS)

This report presents Mississippi\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Mississippi for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Provisional COVID-19 Deaths by HHS Region, Race, and Age

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19 reported to NCHS by time-period, HHS region, race and Hispanic origin, and age group.

United States death counts include the 50 states, plus the District of Columbia and New York City. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City, Puerto Rico; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.
Compound 525252: N''-(4-nitro-phenyl)-N,N,N',N'-tetramethyl-guanidine

Chemical compound data from PubChem database. IUPAC Name: 1,1,3,3-tetramethyl-2-(4-nitrophenyl)guanidine. Molecular Formula: C11H16N4O2. Molecular Weight: 236.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Child Abuse and Neglect Data System (NCANDS) Child File: Findings from the National Child Abuse and Neglect Data System (NCANDS) - Data Tables (From Child Maltreatment 2017)

<p>The National Child Abuse and Neglect Data System (NCANDS) Child File data set consists of child-specific data of all reports of maltreatment to State child protective service agencies that received an investigation or assessment response. NCANDS is a Federally-sponsored national data collection effort created for the purpose of tracking the volume and nature of child maltreatment reporting each year within the United States. The Child File is the case-level component of the NCANDS. Child File data are collected annually through the voluntary participation of States. Participating States submit their data after going through a process in which the State's administrative system is mapped to the NCANDS data structure.  Data elements include the demographics of children and their perpetrators, types of maltreatment, investigation or assessment dispositions, risk factors, and services provided as a result of the investigation or assessment.</p>
Compound 526899: 2-(2-Isopentoxyethoxy)ethyl trifluoroacetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-(3-methylbutoxy)ethoxy]ethyl 2,2,2-trifluoroacetate. Molecular Formula: C11H19F3O4. Molecular Weight: 272.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400110-T1: [Translated] PROCEDURE FOR MANAGING A VIRTUAL PRIVATE NETWORK

The present invention discloses a method for managing a Virtual Private Network (VPN). In the method, basic display elements of corresponding icons in a topology view are determined, and corresponding relationships between VPN states and icon displayed states are set up; the method further includes the following steps: a network management system collects state information of all VPNs in the network; setting and displaying the state of each icon according to the obtained VPN state information and the corresponding relationships between the VPN states and the icon displayed states. The method of the present invention makes it possible to quickly understand and monitor the states of all the VPNs currently operating in the network.